



# Supplementary Materials: KRAS<sup>G12C</sup> Can Either Promote or Impair Cap-Dependent Translation in Two Different Lung Adenocarcinoma Cell Lines

George Kyriakopoulos, Vicky Katopodi, Ilias Skeparnias, Eleni G. Kaliatsi, Katerina Grafanaki and Constantinos Stathopoulos


## Supplementary Figures




**Figure S1.** Generation of A549 and CL1-5 KRAS<sup>G12C</sup> Tet-inducible stable cell lines. **(A)** TALE Nucleases Left and Right are designed to induce a double-strand break at a specific point on the AAVS1 locus of the human genome. Homologous recombination with the homology arms of the construct containing the TRE3G promoter and the KRAS4B c.34G>T gene sequence were incorporated into the specific locus. After clonal selection, addition of doxycycline in the chosen clones' medium led to almost 3-fold upregulation of KRAS4B c.34G>T gene. The expression levels are shown as relative expression compared to the levels of endogenous KRAS gene of the control cells (dotted line) using the  $2^{-\Delta\Delta Ct}$  method. Data are compared by using unpaired Student's t-test and are presented as means $\pm$ SD of biological triplicates. *P*-values are indicated with \**p* < 0.05; \*\**p* < 0.01; \*\*\**p* < 0.001. **(B)** Confirmation of the selected clonal cell cultures from A549 and CL1-5 cells by PCR using a set of primers that amplifies the expected 1033bps PCR product only if the construct is integrated at the AAVS1 locus. In CL1-5 cells both clones were positive and clone #1 was selected and in A549 cells clone #2 was positive.



**Figure S2.** Expression levels of BCL2 family members and mitochondrial ROS production. (**A and B**) The mRNA levels of key members of the BCL2 family were measured by RT-qPCR after short-term (72 h) and long-term (>1 month) induction of KRAS<sup>G12C</sup> in A549 and CL1-5 cells. All levels are shown as relative expression compared to the control (dotted line) using the  $2^{-\Delta\Delta C_t}$  method. Data are compared by using unpaired Student's t-test and are presented as means $\pm$ SD of biological triplicates. P-values are indicated with \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ . (**C**) Mitochondrial ROS production were measured by MitoSOX staining and flow cytometry after short-term (72 h) and long-term (>1 month) induction of KRAS<sup>G12C</sup> in A549 and CL1-5 cells. ROS levels are shown as relative (%) MFI levels upon MitoSOX staining compared to the control (dotted line). Data are compared by using unpaired Student's t-test and are presented as means $\pm$ SD of biological triplicates. P-values are indicated with \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ .



**Figure S3.** mRNA levels of key components of MAPK and PI3K/AKT/mTOR signaling pathways. Expression levels of genes involved in MAPK and PI3K/AKT/mTOR signaling pathways after induction of KRAS<sup>G12C</sup> in A549 and CL1-5 cells, as identified by RT-qPCR. All levels are shown as relative expression compared to the control (dotted line) using the  $2^{-\Delta\Delta C_t}$  method. Data are compared by using unpaired Student's t-test and are presented as means $\pm$ SD of biological triplicates. *P*-values are indicated with \**p* < 0.05; \*\**p* < 0.01; \*\*\**p* < 0.001.



**Figure S4.** Expression profile of genes involved in the fidelity of start codon selection and cap-dependent translation. (A) The mRNA levels of key components involved in the fidelity of mRNA scanning were measured by RT-qPCR after induction of KRAS<sup>G12C</sup> in A549 and CL1-5 cells. (B) The expression profile of *EIF2S1* gene and the genes coding for members of the eIF4F complex was identified by RT-qPCR after induction of KRAS<sup>G12C</sup> in A549 and CL1-5 cells. All levels are shown as relative

expression compared to the control (dotted line) using the  $2^{-\Delta\Delta C_t}$  method. Data are compared by using unpaired Student's *t*-test and are presented as means $\pm$ SD of biological triplicates. *P*-values are indicated with \**p* < 0.05; \*\**p* < 0.01; \*\*\**p* < 0.001.

## Supplementary Tables

**Table 1.** List of antibodies used for Western blot analysis.

Antibody	RRID	Catalog No.	Clone	Company
$\beta$ -Actin	AB_330288	4967	polyclonal	Cell Signaling
phospho-ERK	AB_627545	sc-7383	E-4	Santa Cruz Biotech.
ERK 1/2	AB_2141283	sc-135900	MK1	Santa Cruz Biotech.
phospho-AKT (S473)	AB_329825	9271	polyclonal	Cell Signaling
phospho-mTOR (S2448)	AB_10691552	5536	D9C2	Cell Signaling
mTOR	AB_2105622	2983	7C10	Cell Signaling
RAPTOR	AB_2130791	sc-81537	10E10	Santa Cruz Biotech.
RICTOR	AB_10611167	sc-271081	H-11	Santa Cruz Biotech.
phospho-p70-S6K (T389)	AB_2269803	9234	108D2	Cell Signaling
p70-S6K	AB_331676	9202	polyclonal	Cell Signaling
I $\kappa$ B- $\alpha$	AB_627772	sc-1643	H-4	Santa Cruz Biotech.
eIF1/1B	N/A	sc-390122	B-2	Santa Cruz Biotech.
phospho-eIF2 $\alpha$ (S51)	AB_330951	9721	polyclonal	Cell Signaling
eIF2 $\alpha$	AB_2230924	9722	polyclonal	Cell Signaling
eIF5	AB_627507	sc-28309	E-10	Santa Cruz Biotech.
eIF5B	N/A	sc-393564	D-9	Santa Cruz Biotech.
phospho-eIF4E (S209)	AB_331677	9741	polyclonal	Cell Signaling
eIF4E	AB_2097675	2067	C46H6	Cell Signaling
phospho-4E-BP1 (S65)	AB_823413	9456	174A9	Cell Signaling
4E-BP1	AB_2097841	9644	53H11	Cell Signaling
c-MYC	AB_627266	sc-47694	9E11	Santa Cruz Biotech.
anti-puromycin	AB_2566826	MABE343	12D10	Millipore

**Table S2.** List of primers used for gene expression analysis.

Gene	Forward	Reverse
ACTB	AGCGAGCATCCCCAAAGTT	GGGCACGAAGGCTCATCATT
BAK	TGCATTTGGCTGAATCAAGAAGTT	AGTGGGAGAAGGACTATCAACACC
BAX- $\alpha$	TCAGGATGCGTCCACCAAGAAGC	TGAGCACTCCCGCCACAAAGATG
BCL2	GCACTTCTCCCGCCGCTACCGC	AGGCCGCTGCTGGGGCCGAC
BCL6	CATGCAGAGATGTGCTCCACA	TCAGAGAAGCGGCAGTCACACT
BCL-XL	GGAAAGCGTAGACAAGGAGATGC	GGTGGGAGGGTAGAGTGGATGGT
KRAS4B	CAAGAGCGCCTTGACGATACA	CCAAGAGACAGGTTTCTCCATC
PTEN	GTGGAGTTTACCGGCAGCAT	CTGGCAGGTAGAAGGCAACT
c-MYC	TCCATGAGGAGACACCGCCCA	TGGGGCTGGTGCATTTTCGGT
MAPK1	CGCCGAAGCACCATTCAAG	AGAACACCGATGTCTGAGCA
AKT1	ATGCAGCATCGTTCTTTGC	TGATCATCTGGGCCGTGAAC
AKT2	ACCACAGTCATCGAGAGGACC	GGAGCCACACTTGTAGTCCA
mTOR	AGCTGCCAAGTGCCGAGCAT	AGCAGCCATCCGGGCCATCTT
RPTOR	ATTCCCACCGCTCACTCATC	TTGACGCTCACACTCACGAT
RICTOR	TTTTTCGGGGATTCTGGATGC	GACAGCAAATGGGAAACCTCA
RPS6KB	TTGGTCAGGCAGTCAACACT	TGCAGGACACGTGGAGTAAC
EIF1/1B	TGTCCAAGGGATCGCTGATG	TTCAGTGAGCCACAAGCACT
EIF2S1	AATAGGCGCTTGACCCAC	TGTTCTCTCCAGGGTTGTCC
EIF5	GCTCCGTATCCAGCAGTGAG	CATTTCGACGCCTTTGAGCTT
EIF5B	GGGTGTTGAAGTGCCATCAAA	CCAATCATCCAATCCAGCATCC
EIF4AI	TATGACCTTCCCACCAACAGG	CCTCAGATGAGGTCAGCAACA

<i>EIF4GI</i>	TTTGAGACTCCCCTCCGAGT	CCTCGTCATACAGTGCGTCA
<i>EIF4E</i>	AGGACTGAAACCACCCTCCAGCA	TCGGGGGATTAGGAGTAGGGGTGG
<i>EIF4EBP1</i>	TCCTTGTGCCTCCACTGATG	CTAAGGAAGGGGTGTTGCG

**Table S3.** List of primers used for miRNAs expression analysis.

Primers	Sequence
oligodT adapter	GCGAGCACAGAATTAATACGACTCACTATAGGTTTTTTTTTTTTVN
Outer primer	GCGAGCACAGAATTAATACGACT
miR-103	AGCAGCATTGTACAGGGCTATGA
miR-26a-5p	TTCAAGTAATCCAGGATAGGCT
miR-26b-5p	TTCAAGTAATTCAGGATAGGT
miR-92a-3p	TATTGCACTTGTCCCGGCCT
hsa-let-7a-5p	TGAGGTAGTAGGTTGTATAGTT
hsa-let-7b-5p	TGAGGTAGTAGGTTGTGTGGTT
hsa-let-7c-5p	TGAGGTAGTAGGTTGTATGGTT
hsa-let-7d-5p	AGAGGTAGTAGGTTGCATAGTT
hsa-let-7e-5p	TGAGGTAGGAGGTTGTATAGTT
hsa-let-7f-5p	TGAGGTAGTAGATTGTATAGTT
hsa-let-7g-5p	TGAGGTAGTAGTTTGTACAGTT
hsa-let-7i-5p	TGAGGTAGTAGTTTGTGCTGTT